14.87
price down icon3.31%   -0.52
 
loading
Zymeworks Inc. stock is traded at $14.87, with a volume of 211.04K. It is down -3.31% in the last 24 hours and up +10.39% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$15.39
Open:
$15.37
24h Volume:
211.04K
Relative Volume:
0.46
Market Cap:
$1.05B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
5.3107
EPS:
2.8
Net Cash Flow:
$-96.01M
1W Performance:
-14.14%
1M Performance:
+10.39%
6M Performance:
+63.16%
1Y Performance:
+81.68%
1-Day Range:
Value
$14.83
$15.40
1-Week Range:
Value
$14.83
$17.70
52-Week Range:
Value
$7.97
$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name
Name
Zymeworks Inc.
Name
Phone
604-678-1388
Name
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
Employee
170
Name
Twitter
@ZymeworksInc
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ZYME's Discussions on Twitter

Compare ZYME with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ZYME 14.87 1.05B 62.71M -112.51M -96.01M 2.80
VRTX 467.20 119.83B 10.63B -479.80M -1.35B 13.33
REGN 760.34 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 565.93 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.51 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.13 24.08B 3.30B -501.07M 1.03B 11.54

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-21-23 Resumed Wells Fargo Overweight
Jan-04-23 Reiterated H.C. Wainwright Neutral
Dec-20-22 Upgrade Jefferies Hold → Buy
Nov-01-22 Downgrade H.C. Wainwright Buy → Neutral
Oct-21-22 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-04-22 Resumed Wells Fargo Overweight
May-05-22 Upgrade Guggenheim Neutral → Buy
Mar-15-22 Initiated Evercore ISI Outperform
Dec-10-21 Upgrade SVB Leerink Mkt Perform → Outperform
Nov-17-21 Resumed Guggenheim Neutral
Oct-07-21 Initiated Jefferies Hold
Mar-31-21 Initiated Credit Suisse Outperform
Feb-25-21 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-08-21 Resumed H.C. Wainwright Buy
Jan-25-21 Downgrade Citigroup Buy → Neutral
Sep-29-20 Resumed JP Morgan Neutral
Aug-06-20 Initiated SVB Leerink Outperform
Jan-10-20 Initiated Wolfe Research Outperform
Dec-09-19 Initiated JP Morgan Neutral
Nov-25-19 Initiated H.C. Wainwright Buy
Nov-20-19 Initiated Guggenheim Buy
Sep-30-19 Upgrade Raymond James Outperform → Strong Buy
Aug-30-19 Initiated Stifel Buy
Jul-18-19 Initiated Deutsche Bank Buy
May-11-18 Upgrade Barclays Underweight → Equal Weight
Mar-19-18 Initiated Raymond James Outperform
View All

Zymeworks Inc. Stock (ZYME) Latest News

pulisher
Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 11, 2024

Zymeworks stock soars to 52-week high, hits $17.29 - Investing.com India

Nov 11, 2024
pulisher
Nov 11, 2024

Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com UK

Nov 11, 2024
pulisher
Nov 11, 2024

Zymeworks (NYSE:ZYME) Stock Rating Upgraded by Leerink Partners - Defense World

Nov 11, 2024
pulisher
Nov 11, 2024

FY2024 EPS Estimates for Zymeworks Lifted by Leerink Partnrs - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Analysts Update Their Estimates For Zymeworks BC Inc - Stocks Register

Nov 09, 2024
pulisher
Nov 09, 2024

Q4 Earnings Estimate for Zymeworks Issued By Leerink Partnrs - Defense World

Nov 09, 2024
pulisher
Nov 09, 2024

Zymeworks (NYSE:ZYME) Raised to Strong-Buy at Leerink Partnrs - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

Leerink Partnrs Forecasts Zymeworks' Q4 Earnings (NYSE:ZYME) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria

Nov 07, 2024
pulisher
Nov 07, 2024

Leerink lifts Zymeworks stock target on pipeline progress - Investing.com

Nov 07, 2024
pulisher
Nov 06, 2024

Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena

Nov 06, 2024
pulisher
Nov 06, 2024

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World

Nov 06, 2024
pulisher
Nov 05, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire

Nov 05, 2024
pulisher
Nov 05, 2024

Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - The Manila Times

Nov 05, 2024
pulisher
Nov 05, 2024

Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com Canada

Nov 04, 2024
pulisher
Nov 04, 2024

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha

Nov 04, 2024
pulisher
Nov 04, 2024

Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St

Nov 03, 2024
pulisher
Nov 03, 2024

Wells Fargo Downgrades Zymeworks (ZYME) - MSN

Nov 03, 2024
pulisher
Nov 03, 2024

Zymeworks (NYSE:ZYME) Shares Gap Down – Here’s What Happened - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024
pulisher
Nov 02, 2024

Zymeworks Q4 2024 Earnings Preview - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Zymeworks to Spotlight Innovations at Investor Conferences - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Zymeworks (NYSE:ZYME) Shares Gap DownHere's Why - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha

Nov 01, 2024
pulisher
Nov 01, 2024

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St

Nov 01, 2024
pulisher
Nov 01, 2024

Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

HC Wainwright Reiterates Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 01, 2024
pulisher
Nov 01, 2024

Zymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Zymeworks Reports Q3 Results and Strategic Advances - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Zymeworks Advances Biotherapeutic Pipeline in 2024 - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Oct 31, 2024
pulisher
Oct 31, 2024

Zymeworks Q3 2024 Earnings Preview - MSN

Oct 31, 2024
pulisher
Oct 30, 2024

Zymeworks Inc (ZYME) Q3 2024 Earnings Report Preview: What To Lo - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

Zymeworks (NYSE:ZYME) PT Raised to $28.00 at Stifel Nicolaus - Defense World

Oct 30, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Takes Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences - The Korea Bizwire

Oct 29, 2024
pulisher
Oct 28, 2024

Zymeworks (NYSE:ZYME) Price Target Raised to $28.00 at Stifel Nicolaus - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference - GlobeNewswire

Oct 25, 2024

Zymeworks Inc. Stock (ZYME) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.04
price down icon 0.87%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):